Recent studies including the SPRINT trial have shown beneficial effects of intensive systolic blood pressure reduction over the standard approach. The awareness of the J-curve for diastolic blood pressure (DBP) causes some uncertainty regarding the net clinical effects of blood pressure reduction. The current analysis was performed to investigate effects of low on-treatment DBP on cardiovascular risk in the SpRint population. the primary composite outcome was the occurrence of myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure or death from cardiovascular causes. The prevalence of primary outcomes was significantly higher in subjects within low DBP in both standard (44-67 mmHg [10.8%] vs 67-73 mmHg [6.7%] vs 73-78 mmHg [5.1%] vs 78-83 mmHg [4.4%] vs 83-113 mmHg [4.3%], p < 0.001) and intensive treatment (38-61 mmHg [6.7%] vs 61-66 mmHg [4.1%] vs 66-70 mmHg [4.5%] vs 70-74 mmHg [2.7%] vs 74-113 mmHg [3.4%], p < 0.001) arms. After adjusting for covariates, low DBP showed no significant effects on cardiovascular risk. Therefore, while reaching blood pressure targets, low DBP should not be a matter of concern.
Results
A total of 8890 participants (64.7% men, 35.3% women) were included in this study. Among these participants, 4438 (49.9%) of them were allocated to the standard (<140 mmHg) treatment arm while 4452 (50.1%) patients were placed in the intensive treatment arm (<120 mmHg). The primary composite outcome occurred a total of 461 (5.2%) subjects, including 272 (6.1%) from the standard and 189 (4.2%) from the intensive treatment arm. The overall mean SBP/DBP was 128.1/71.4 mmHg, while mean SBP/DBP in standard and intensive treatment arm were 135.3/75.1 mmHg and 120.9/67.7 mmHg.
The quintiles of DBP were calculated for the standard (1 st quintile 44-67 mmHg, 2 nd 67-73 mmHg, 3 rd 73-78 mmHg, 4 th 78-83 mmHg, 5 th 83-113 mmHg) and intensive treatment arm (1 st quintile 38-61 mmHg, 2 nd 61-66 mmHg, 3 rd 66-70 mmHg, 4 th 70-74 mmHg, 5 th 74-113 mmHg). There were significant differences in the occurrence of primary endpoints within quintiles of both treatment arms (standard: 10.8% vs 6.7% vs 5.1% vs 4.4% vs 4.3%, p < 0.001; intensive: 6.7% vs 4.1% vs 4.5% vs 2.7% vs 3.4%, p < 0.001). Kaplan-Meier curves showing survival rates among the arms are presented in Figs 1 and 2 . Log-rank test confirmed significant differences between curves among the DBP quintiles in the standard and intensive treatment arms (p < 0.0001). The clinical characteristics of the quintiles in each treatment arm are shown in Tables 1 and 2. The highest rates cardiovascular and renal disease and older age were observed among the quintiles with the highest incidence of primary endpoints. Despite having lower SBP, worse prognoses were observed in the quintiles with lower DBP. The patients in quintiles with lower DBP received more antihypertensive drugs. The difference in pulse pressure was also observed between the quintiles in both treatment arms. The patients with lower on-treatment DBP had also lower baseline DBP. Higher use of statins and aspirin was associated with better lipid profile, but this result was observed in the quintiles with worse outcomes. Similar findings were observed in both treatment arms.
The primary outcome rates were compared between the corresponding DBP quintiles in standard and intensive treatment arm. When the 1 st and 2 nd quintiles were compared, there was a higher incidence of primary outcomes in the standard treatment arm compared to the intensive treatment arm (10.8% vs 6.7%, p = 0.003 and 6.7% vs 4.1%, p = 0.023). There was no significant difference in between the 3 rd , 4 th and 5 th DBP quintiles in the two treatment arms (5.1% vs 4.5%, p = 0.649; 4.4% vs 2.7%, p = 0.064, 4.3% vs 3.4%, p = 0.342).
Figure 1.
Kaplan-Meier curves with 95% confidence intervals in standard treatment arm. Comparison of curves within DBP quintiles were made using the log-rank test (p < 0.0001). 1st quintile: 44-67 mmHg, 2nd quintile: 67-73 mmHg, 3rd quintile: 73-78 mmHg, 4th quintile: 78-83 mmHg, 5th quintile: 83-113 mmHg.
Among the standard and intensive treatment arms, on-treatment DBP was a poor predictor of primary endpoints. Receiver operating characteristic (ROC) analysis showed the following area under the curve (AUC) measurements: 0.605 (95% CI: 0.569-0.641) and 0.581, 95% CI: 0.536-0.626 ( Fig. 3 ).
We used Cox proportional hazard risk model to assess the impact of on-treatment DBP and pulse pressure on primary endpoint event risks among the total analysed population of patients. After adjusting for age, sex, history of clinical cardiovascular disease or chronic kidney disease, treatment arm, current smoking status and body mass index, our analysis revealed no influence of on-treatment DBP on the occurrence of primary outcome (Table 3) . However, on-treatment pulse pressure was shown to be an independent predictor of primary outcome event risks after adjusting for other cofactors in the multivariable Cox model ( Table 3 ). The analysis comparing participants in the quintiles of total analysed population is shown in Table S1 and Fig. S1 .
Discussion
This study shows that DBP is not an independent risk factor for cardiovascular events. Worse prognoses among participants with low on-treatment DBP may be explained by the fact that these patients were older, often had previous cardiovascular disease or chronic kidney disease and more often were smokers. The impact of those factors on the primary endpoints was high, what is expressed by hazard ratios in Table 3 .
Three other studies based on SPRINT data investigated the J-curve hypothesis of DBP. Kalkman et al. re-analysed merged SPRINT and ACCORD data to verify the J-shaped curve hypothesis related to SBP and DBP 13 . The authors found an increased risk associated with lower on-treatment DBP with a nadir at 85 mmHg, which indicated that their results confirmed J-shaped curve hypothesis. However, the impact of potential interactions between low DBP and confounding variables was not assessed. In our study, the influence of low on-treatment DBP on primary outcomes disappeared after adjusting for confounding factors.
In another paper re-analysing the SPRINT data, Stensrud et al. assumed, according to the results of previous studies, that mean DBP < 60 mmHg may worsen the effects of lowering BP 14, 18 . After adjustment for potential confounding variables, the authors did not observe unfavourable effects of DBP < 60 mmHg. It is important to note that the authors used a cut-off value of DBP < 60 mmHg while in other studies, DBP < 70 mmHg was used as the lower limit for DBP [19] [20] [21] . These results may imply that DBP < 60 mmHg did not increase patients' risk when cofactors were included in the analysis. Also, recent European guidelines selected DBP = 70 mmHg as a lower limit for recommended on-treatment DBP 3 . The role of pulse pressure should be also emphasised here. We found that on-treatment pulse pressure is an independent risk factor for primary endpoint events, even after adjusting for confounding factors. In the study examining SPRINT data, Pareek et al. showed that the excess risk associated with higher pulse pressure at baseline appeared to be related to age, sex and other major cardiovascular risk factors, thus limiting its clinical utility among high-risk SPRINT patients 22 . Authors concluded that baseline pulse pressure should not limit the selection of appropriate candidates for intensive BP reduction. However, some studies found that baseline pulse pressure might be an independent risk factor for acute coronary events 23 .
The SPRINT data analysis was also performed by Lee et al. 15 . The authors determined that DBP < 55 mmHg at during a single visit was associated with adverse clinical effects. The adopted methodology evaluated the effect of single episode of hypotension rather than examining the effect of permanently low on-treatment DBP on adverse events. In contrast to the results of a study by Stensrud et al., DBP < 55 mm at a single visit significantly increased the risk of complications according to the results of a multivariable Cox proportional analysis.
According to the results of previous SPRINT re-analyses, our study involved the comparison within the quintiles of DBP in both treatment arms. This methodology helped reveal the key differences within subpopulations across on-treatment DBP levels and the necessity of assessing the impact of confounding factors.
The results of other studies investigating the DBP-related J-curve hypothesis were ambiguous. The differences between analysed endpoints, DBP thresholds and study populations (baseline prevalence of CAD, diabetes mellitus or stroke) made it difficult to draw clear conclusions and compare results with our results.
The results of HOT trial (Hypertension Optimal Treatment) did not reveal differences in the incidence of stroke risk, overall and cardiovascular-related mortality and myocardial infarction between the subgroups with DBP ≤90, ≤85 and ≤80 mmHg. The incidence of all myocardial infarctions was almost significant, and the authors concluded that optimal DBP is 82.6 mmHg 10 . In the Hypertension Objective Treatment Based on Measurement by Electrical Devices study (HOMED-BP), the impact of usual (125-134/80-84 mmHg) vs. tight (<125/80 mmHg) BP control was investigated 24 . The authors did not evidence regarding a J-shaped curve relationship between BP reduction and clinical endpoints 24 . According to the J-shaped curve hypothesis, low compliance among the tight control arm, on-treatment DBP may be higher than unsafe BP levels. Post-hoc analyses of The Valsartan Antihypertensive Long-Term Use Evaluation and INVEST trials did not provide data on the detrimental effects of low on-treatment DBP 11, 25 . Other re-analyses confirmed the J-shaped hypothesis for on-treatment DBP in subjects of Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Table 1 . Characteristics of DBP quintiles within the standard treatment arm. Continuous data are presented as mean ± standard deviation, discrete as a number with percentage. SBP -systolic blood pressure, DBP -diastolic blood pressure, PP -pulse pressure, p-value calculated for comparison within quintiles.
Trial (ONTARGET) and merged ONTARGET and Telmisartan Randomised Assessment Study in ACE Intolerant
Participants with Cardiovascular Disease (TRANSCEND) trials 12, 19, 26 . The J-shaped curve relationship between DBP and cardiovascular mortality was also observed after long-term follow-up in the analysis of the National Health and Nutrition Examination Survey III and Diabetes Heart Study performed by Gomadam et al. 27 Our multivariable Cox model showed that DBP was not a significant cofactor. Based on the data obtained from this study and previous studies, the evidence for a J-shaped relationship between DBP and cardiovascular risk is inconclusive. Despite the weakness of evidence regarding the J-shaped curve hypothesis, this phenomenon is more pronounced in the subjects with CAD 28, 29 . Furthermore, CAD is more frequent in the subjects with lower DBP, which suggests that this effect may be cumulative 20, [30] [31] [32] . In our analysis of individuals with a high risk of cardiovascular disease, including current CAD patients, we found no evidence that a J-shaped curve existed for on-treatment DBP when some cofactors were included into the analysis. Despite the fact that coronary blood flow primarily occurs during diastole and depends on DBP, it should be emphasised that the clinical effects of DBP cannot be interpreted separately from on-treatment SBP. It is difficult to decide on a patient-by-patient basis whether the benefit of intensive SBP reduction outweighs the harms associated with low DBP. Beddhu et al. evaluated the interaction between low baseline DBP and intensive SBP reduction among SPRINT participants and found adverse effects associated with intensive treatment to lower SBP among patients with low baseline DBP 33 . Our comparison of corresponding quintiles of DBP in both treatment arms suggests better outcomes are associated with intensive rather than standard treatment, despite lower on-treatment DBP. According to these results, on-treatment DBP should be only interpreted as the consequence of SBP lowering and SBP < 130 mmHg should be considered a treatment goal.
The most important limitation to our study is the fact that despite the large sample size, post-hoc reasoning could be affected by potential bias. Secondly, there were essential differences identified between automated and clinical BP measurements. Therefore, it was difficult to compare our results to those of the SPRINT trial due to differences in methods 34, 35 . The studies performed by Kalkman, Stensrud and Lee had the same disadvantage; therefore, their choice of corresponding harmful DBP threshold may be also questioned. Furthermore, our findings do not apply to diabetic subjects or these with the history of stroke. However, the ACCORD and SPS3 trials www.nature.com/scientificreports www.nature.com/scientificreports/ already investigated these subgroups 17, 18 . Considering the results of Di Nora et al., who showed that the SPRINT results were not reproducible within a community-based cohort of Caucasian participants, our results could also vary based on the characteristics of the investigated population 36 .
In conclusion, our data showed that low on treatment DBP does not independently influence cardiovascular risk in patients allocated to intensive and standard blood pressure lowering strategies. These results are in line with the conclusions of similar studies [11] [12] [13] [14] 27 . In that context, low on-treatment DBP should be considered as a marker of high cardiovascular risk rather than an independent risk factor 26 .
Methods
Study population. SPRINT was a randomised and multi-centre study that determined whether patients benefitted from intensive efforts to decrease SBP 1 . Participants were randomised to intensive (target SBP < 120 mmHg) and standard treatment (target SBP < 140 mmHg) arms. Although a target of DBP was not established, patients were treated to achieve DBP of <90 mmHg after meeting their goal SBP measurement 37 . Nearly 10,000 subjects who presented high risks of cardiovascular diseases and adverse cardiovascular events Table 3 . Cox proportional hazard risk model evaluating the impact of on-treatment DBP (Model A) or ontreatment pulse pressure (Model B) and other predictors on primary outcome occurrence. BMI -body mass index, DBP -diastolic blood pressure.
